Workshop n°1
Monday, 22 September 2025
Upskilling Bioproduction Teams in Data Analysis and ATMP Bioprocesses through Innovative Digital Learning
14h00
Workshop Overview
Discover how Immerscio.bio, a training organization dedicated to biomanufacturing, supports workforce upskilling through two new digital learning programs
• Data analysis across the bioproduction lifecycle
- Plenary
This program covers the full data lifecycle in biomanufacturing, from process design to commercial production. Learners explore how data is generated (ERP, MES, LIMS, ..), structured, and governed, and how it supports continuous improvement, regulatory compliance, and operational efficiency. The program introduces key concepts in data architecture, statistical analysis, and IA & modeling methods for process optimization, using real-life case studies.
• Bioprocesses for Advanced Therapy Medicinal Products (ATMPs)
This program introduces the fundamentals and regulatory landscape of Advanced Therapy Medicinal Products, including gene therapy, RNA-based strategies, and cell/tissue engineering. Learners explore biomanufacturing processes specific to viral and non-viral vectors, as well as industrial scale-up challenges, through real-world case studies and digital simulations.
This interactive session includes a live demonstration of our digital platform and an open questions on Immerscio digital platform and workforce training.
Workshop Program
- Introduce Immerscio.bio’s digital training approach
- Explore the structure and objectives of the 2 new learning packs on Data & ATMPs
- Live demo an interactive session on Immerscio.bio learning Platform
Workshop Facilitators
François RAGOT
Bioproduction Expert
Immerscio.bio, France
Céline ROCCA
Head of Pedagogical Committee
Campus Biotech Digital, France
Cynthia HITTI
Business Developer
Immerscio.bio, France
Workshop n°2 - Part I
Tuesday, 22 September 2026
11h10
Best Practices in Host Cell Impurity Analytics - Using Advanced Technologies and Methods to Monitor and Control Host Cell Proteins
- Plenary
Chairman
Workshop Overview
Host cell protein (HCP) impurities are the main process-related impurities in biological drugs and can pose a risk to patients and affect drug efficacy and stability. As a critical quality attribute, HCP levels must be carefully monitored and controlled to ensure product safety and efficacy.
HCP analytics have come a long way over the last 25 years. We have gone from a “black box” type approach that produced numbers that were semiquantitative at best to groundbreaking Mass Spectrometry techniques that can identify every host cell protein in a Drug Substance sample. HCP ELISA remains the workhorse for HCP analytics due to its utility, simplicity, robustness, and cost-effective nature. But we now have the tools to know exactly which HCP the assay can detect and which ones it will miss.
We will discuss how adoption of advanced technologies and methods for HCP analytics ensure that an HCP ELISA, whether it is a generic or a process-specific assay, is appropriate for use and allows data driven risk assessment to ensure drug product integrity and safety. Several case studies focusing on HCP antibody coverage assessment utilizing 2D PAGE- and MS-based methods will be presented. Additionally, data on LC-MS based HCP relative and absolute quantification will be presented.
Presenter
John LOCKLEAR
Associate Director - Assay Development and Technical Support
Cygnus Technologies
Workshop n°2 - Part II
Wednesday, 23 September
11h10
Analytics for Other Process-related Impurities in Biologics: Protein A, Protein L, Host Cell DNA
- Plenary
Chairman
Workshop Overview
An overview of other host cell and process-related impurities, such as Protein A and Protein L Ligand Leachates, Host Cell DNA and requirements for impurity testing. Data and case studies utilizing Cygnus Technologies novel solutions for the reproducible detection and quantification of these impurities will be presented.
Presenter
John LOCKLEAR
Associate Director - Assay Development and Technical Support
Cygnus Technologies
Workshop n°3
Tuesday, 22 September 2026
Optimising Biologic Drug Products: Connecting Formulation Science, Process Development and Advanced Analytics
11h10
Optimising Biologic Drug Products: Connecting Formulation Science, Process Development and Advanced Analytics
- Plenary
Chairman
Summary
The development of robust biologic drug products requires analytical strategies that provide insight from molecular structure to particle formation. In this workshop, Jean-François Boé, PhD (Senior Director, Drug Product Development, Catalent) and Waters experts will demonstrate how complementary analytical technologies, including liquid chromatography (LC), mass spectrometry (MS), multi-angle and dynamic light scattering (MALS and DLS), and Aura™ backgrounded membrane imaging, can be applied throughout formulation and process development.
Using real-world examples, attendees will learn how these orthogonal techniques can be used to characterise molecular variants, monitor aggregation and particle formation, assess formulation stability, and evaluate the impact of process changes on product quality. Join us to discover how integrated analytical workflows can accelerate development, strengthen process understanding, and support the creation of stable, manufacturable biologic drug products.
Speakers
Ben WILKES
Principal Biologics Market Development Manager
Waters Corporation, UK
Jean-François BOE
Senior Director, Drug Product Development
Catalent Biologics